Azithromycin: A review of its use in paediatric infectious diseases

Drugs

Volumn 56, Issue 2, 1998, Pages 273-297

  Langtry, Heather D ^a,b   Balfour, Julía A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFACLOR; CLARITHROMYCIN; ERYTHROMYCIN; PENICILLIN V;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BRONCHITIS; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; META ANALYSIS; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; ORAL DRUG ADMINISTRATION; OTITIS MEDIA; PHARYNGITIS; PNEUMONIA; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; TONSILLITIS;

CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; HAEMOPHILUS INFLUENZAE; LEGIONELLA; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 0031846533     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856020-00014     Document Type: Review

References (135)

1. Peters DH, Friedel HA, McTavish D. Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992 Nov; 44: 750-99
2. Dunn CJ, Barradell LB. Azithromycin: a review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 1996 Mar; 51: 483-505
3. NCCLS. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Fourth Edition; Approved Standard. NCCLS document M7-A4 (ISBN 1-56238-309-4) NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087
4. Doern GV, Brueggemann A, Holley Jr HP, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from out-patients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996 May; 40 (5): 1208-13
5. Barry AL, Fuchs PC. In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens. Antimicrob Agents Chemother 1995 Jan; 39 (1): 238-40
6. Barry AL, Pfaller MA, Fuchs PC, et al. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from US medical centers in 1992 and 1993. Antimicrob Agents Chemother 1994 Oct; 38 (10), 2419-25
7. Barry AL, Fuchs PC, Brown SD. Relative potencies of azithromycin, clarithromycin and five other orally administered antibiotics [letter]. J Antimicrob Chemother 1995 Apr; 35: 552-5
8. Brown S, Barry AL, Burton P. Susceptibility surveillance of U.S. respiratory pathogen isolates to newer macrolide and azalide antibiotics. Int J Antimicrob Agents 1996; 7: 53-8
9. Gerardo SH, Citron DM, Claros MC, et al. Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. Antimicrob Agents Chemother 1996 Oct; 40: 2413-5
10. Matsunaga T, Shimohira H, Oishi S, et al. In vitro and in vivo antimicrobial activity of azithromycin, a new macrolide antibiotic [in Japanese]. Jpn J Chemother 1995 Dec; 43 Suppl. 6: 68-83
11. Nagashima M, Tateda K, Matsumoto T, et al. In vitro and in vivo antibacterial activity of azithromycin, a new azalide antibiotic [in Japanese]. Jpn J Chemother 1995 Dec; 43 Suppl. 6: 8-23
12. Ednie LM, Visalli MA, Jacobs MR, et al. Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. Antimicrob Agents Chemother 1996 Aug; 40: 1950-2
13. Fass RJ. In vitro activity of Bay y 3118, a new quinolone. Antimicrob Agents Chemother 1993 Nov; 37 (11): 2348-57
14. Nishino T, Komoto A, Otsuki M. In vitro and in vivo antibacterial activity of azithromycin, a new macrolide antibiotic [in Japanese]. Jpn J Chemother 1995 Dec; 43 Suppl. 6: 40-54
15. Platsouka E, Constantoulaki S, Dimitropoulos N, et al. A comparison of in vitro activity of ten oral antimicrobial agents against respiratory tract pathogens. J Chemother 1995; 7 Suppl. 4: 58-60
16. Fass RJ. Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. Antimicrob Agents Chemother 1993 Oct; 37: 2080-6
17. Bauernfeind A. In-vitro activity of dirithromycin in comparison with other new and established macrolides. J Antimicrob Chemother 1993; 31 Suppl. C: 39-19
18. Goldstein EJ, Neshit CA, Citron DM. Comparative in vitro activities of azithromycin. Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates. Antimicrob Agents Chemother 1995 May; 39: 1097-100
19. Van-Asselt GJ, Sloos JH, Mouton RP, et al. Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro. J Med Microbiol 1995 Nov; 43: 386-91
20. Coonan KM, Kaplan EL. In vitro susceptibility of recent North American group A streptococcal isolates to eleven oral antibiotics. Pediatr Infect Dis J 1994 Jul; 13: 630-5
21. Cellesi C, Chigiotti S, Zanchi A, et al. Susceptibility of macrolide and beta-lactam antibiotics of Streptococcus pyogenes strains isolated over a four-year period in central Italy. J Chemother 1996 Jun; 8: 188-92
22. Gnarpe J, Eriksson K, Gnarpe H. In vitro activities of azithromycin and doxycyclitie against 15 isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 1996 Aug; 40: 1843-5
23. Welsh L, Gaydos C, Quinn TC. In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniea. Antimicrob Agents Chemother 1996 Jan; 40: 212-4
24. Agaefidan A, Moncada J, Schachter J. In vitro activity of Azithromycin (CP-62.993) against Chlamydia trachomatis and Chlamydia pneumoniae, Antimicrob Agents Chemother 1993 Sep; 37: 1746-8
25. Lefevre JC, Escaffre MC, Courdil M, et al. In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamydia trachomatis. Pathol Biol Paris 1993 Apr; 41: 313-5
26. Chiarini F, Mansi A, Tomao P, et al. Chlamydia trachomatis genitourinary infections: laboratory diagnosis and therapeutic aspects. Evaluation of in vitro and in vivo effectiveness of azithromycin. J Chemother 1994 Aug; 6: 238-42
27. Höffler D, Koeppe P, Paeske B. Pharmacokinetics of azithromycin in normal and impaired renal function. Infection 1995 Nov-Dec; 23: 356-61
28. Reda C, Quaresima T, Pastoris MC. In vitro activity of six intracellular antibiotics against Legionella pneumonphila strains of human and environmental origin. J Antimicrob Chemother 1994; 33: 757-64
29. Chen SCA, Paul ML, Gilbert GL. Susceptibility of Legionella species to antimicrobial agents. Pathology 1993; 25: 180-3
30. Delmee M, Carpentier M, Glupezynski Y, et al. In vitro susceptibilities of 180 clinical isolates of Haemophilus influenzae to ampicillin, amoxycillin/clavulanate, cefactor, cefuroxime, cefotaxime, clarithromycin, and azithromycin. Acta Clin Belg 1996; 51: 237-43
31. Doern GV, Brueggemann AB, Pierce G, et al. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of β-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob Agents Chemother 1997 Feb; 41 (2): 292-7
32. Ishida K, Kaku M, Irifune K, et al. In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. Antimicrob Agents Chemother 1994 Apr; 38: 790-8
33. Ramadan MA, Tawfik AF, Shibl AM, et al. Posi-antibiotic effect of azithromycin and erythromycin on streptococcal susceptibility to phagocytosis. J Med Microbiol 1995 May; 42: 362-6
34. Odenholt-Tornqvist I, Löwdin E, Cars O. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. Antimicroh Agents Chemother 1995 Jan; 39: 221-6
35. Pediatric SG of A. Pharmacokinetic and clinical studies with azithromycin (fine granule) in the pediatric field [in Japanese]. Jpn J Antibiot 1445 Sep; 48: 1051-73
36. Pediatric SG of A. Pharmacokinetic and clinical studies with azithromycin (capsule) in the pediatric field [in Japanese]. Jpn J Antibiot 1995 Sep; 48: 1074-42
37. Nahata MC, Koranyi KI, Gadgil SD, et al. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. Antimicrob Agents Chemother 1993 Feb; 37: 314-6
38. Nahata MC, Koranyi KI, Luke DR, et al. Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. Antimicrob Agents Chemother 1445 Aug; 34: 1875-7
39. Stevens RC, Reed MO, Shenep JL, et al. Pharmacokinetics of azithromycm after single- and multiple-doses in children. Pharmacotherapy 1997: 17 (5): 874-80
40. Carbon C. Clinical relevance of intracellular and extracellular concentrations of macrolides. Infection 1995; 23 Suppl. 1: 10-4
41. Pukander J, Rautianen M. Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children. J Antimicrob Chemother 1996 Jun; 37 Suppl. C: 53-61
42. Vaudaux BP, Cherpillod J, Dayel P. Concentrations of azithromycin in tonsillar and/or adenoid tissue from paediatric patients. J Antimicrob Chemother 1996 Jun; 37 Suppl. C: 45-51
43. Scaglione F, Pintucci JP, De Martini G, et al. Concentrations of ceftibuten, cefixime and azithromycin in middle ear fluid [abstract]. 36th ICAAC 1996 Sep 15: 14
44. Foulds G, Luke DR, Teng R, et al. The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. J Antimicrob Chemother 1996 Jun; 37 Suppl. C: 37-44
45. Sifrim D, Matsuo H, Janssens J, et al. Comparison of the effects of midecamycin acetate and azithromycin on gastrointestinal motility in man. Drugs Exp Clin Res 1994; 20(3): 121-6
46. Akita H, Sato Y, Kusumoto Y, et al. Bacteriological, pharmacokinetic and clinical evaluation of azithromycin in the pediatric field [in Japanese]. Jpn J Antibiol 1996 Oct; 49: 889-916
47. Motohiro T, Nagai K, Yamada S, et al. Clinical study on azithromycin in 10% fine granules and 100 mg capsules in the field of pediatrics [in Japanese]. Jpn J Antibiot 1997 Mar; 50: 272-47
48. Toyonaga Y, Ishihara T, Nakamura H. Pharmacokinetic and clinical evaluation of azithromycin using fine granules or capsules in the pediatric patients [in Japanese]. Jpn J Antibiot 1996 Nov; 49: 981-93
49. Kitamura K, Kamiya H, Nakano T, et al. Pharmacokinetic and clinical evaluation of azithromycin in the pediatric field [in Japanese]. Jpn J Antibiot 1997 Feb; 50: 206-14
50. Shiba K, Yoshida M, Sakai O, et al. Pharmacokinetics of azithromycin in patients with renal failure [in Japanese]. Jpn J Chemother 1995 Dec; 43 Suppl. 6: 186-92
51. Arguedas A, Loaiza C, Herrera M, et al. Comparative trial of 3-day azithromycin versus 10-day amoxycillin/clavulanate potassium in the treatment of children with acute otitis media with effusion. Int J Antimicrob Agents 1996; 6 (4): 233-8
52. Aronovitz G. A multicenter, open label trial of azithromycin vs amoxicillin/clavulanate for the management of acute otitis media in children. Pediatr Infect Dis J 1996 Sep. 15 Suppl.: 15-9
53. Daniel RR. Comparison of azithromycin and co-amoxiclav in the treatment of otitis media in children. J Antimicrob Chemother 1993 Jun; 31 Suppl. E: 65-71
54. Khurana CM. A multicenter, randomized, open label comparison of azithromycin and amoxicillin/clavulanate in acute otitis media among children attending day care or school. Pediatr Infect Dis J 1996 Sep; 15 Suppl.: 24-9
55. Khurana CM. Safety and advantages of azithromycin in comparison with amoxicillin/clavulanate in otitis media patients attending day care [abstract]. 4th International Conference on the Macrolides, Azalides, Streptogramins and Ketolides; 1918 Jan 21-23; Barcelona, Spain
56. McLinn S. A multicenter, double blind comparison of azithromycin and amoxicillin/clavulanate for the treatment of acute otitis media in children. Pediatr Infect Dis J 1996 Sep; 15 Suppl.: 20-3
57. Pestalozza G, Cioce C, Facchini M. Azithromycin in upper respiratory tract infections: a clinical trial in children with otitis media. Scand J Infect Dis 1992; 24 Suppl. 83: 22-5
58. Principi N. Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media. Eur J Clin Microbiol Infect Dis 1995 Aug; 14: 669-76
59. Schaad UB. Multicentre evaluation of azithromycin in comparison with co-amoxiclav for the treatment of acute otitis media in children. J Antimicrob Chemother 1993 Jun; 31 Suppl. E: 81-8
60. Mohs E, Rodriguez-Solares A, Rivas E. A comparative study of azithromycin and amoxycillin in paediatric patients with acute otitis media. J Antimicrob Chemother 1993 Jun; 31 Suppl. E: 73-9
61. Arguedas A, Loaiza C, Rodriguez F, et al. Comparative trial of 3 days of azithromycin versus 10 days of clarithromycin in the treatment of children with acute otitis media with effusion. J Chemother 1997 Feb; 9: 44-50
62. Peterson J, Treadway G. Azithromycin Otitis Media Study Group. An open comparative study of the efficacy, safety and toleration of azithromycin suspension compared with clarithromycin suspension in the treatment of pediatric patients with acute otitis media [abstract]. 4th International Conference on the Macrolides, Azalides. Streptopramins and Ketolides: 1998 Jan 21-23; Barcelona, Spain
63. Ramet J, Belgian Paediatrician Clarithromycin Workgroup. Comparative safety and efficacy of clarithromycin and azithromycin suspensions in the short course treatment of children with acute otitis media. Clin Drug Invest 1995 Feb: 9: 61-6
64. Rodriguez AF. An open study to compare azithromycin with cefaclor in the treatment of children with acute otitis media. J Antimicrob Chemother 1996 Jun; 37 Suppl. C: 63-9
65. Dagan R, Liebowiz E, Jacobs M, et al. Bacteriological response to acute otitis media (AOM) caused by Haemophilus influence (HI) treated with azithromycin (AZ). [abstract no. K-102]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1997 Sep 28-Oct 1: Toronto, Canada
66. Dagan R, Piglansky L, Yagupsky P, et al. Bacteriologic response in acute otitis media(AOM): comparison between azithromycin (AZ), cefaclor (CEC) and amoxicillin (AMOX). [abstract no. K-103]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1997 Sep 28-Oct 1; Toronto, Canada
67. Arguedas A, Rodriguez A, Louisa C, et al. Azithromycin vs amox/clav in pediatric community-acquired LRTIs. Infect Med 1997 Oct; 10: 807-14
68. Harris J, Campbell M, Kolokathis A, et al. Safety and efficacy of azithromycin in the treatment of community acquired pneumonia in children [abstract]. 36th ICAAC 1990 Sep 15: 286
69. Franckar G, Waelbroeck A, Demol P, et al. Azithromyicin vs erythromycin in the treatment of lower respiratory tract infections in children [abstract]. 7th Eur Congr Clin Microbiol Infect Dis 1995: 269
70. Hofmann D, Schäfer V, Springsklee M. Treatment of children with bacterial lower respiratory tract infections: results of a comparative study of azithromycin vs cefaclor [in German]. MMW Munch Med Wochenschr 1996 May 17; 138: 358-63
71. Principi N, Marchisio P, Biasini G, et al. Azithromycin versus erythromycin in the treatment of paediatric community-acquired pneumonia. Eur J Clin Res 1993; 4: 127-33
72. Ronchetti R, Blasi F, Grossi E, et al. The role of azithromycin in treating children with community-acquired pneumonia. Curr Ther Res 1994 Aug; 55: 965-70
73. Roord JJ, Wolf BHM, Goossens MMHT, et al. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections. Antimicrob Agents Chemother 1996 Dec; 40: 2765-8
74. Sufliarska S, Kuková Z, Nogeová A, et al. Azithromycine (AZI) once daily, compared with cefuroximaxetil (CAX) twice daily in initial therapy of community acquired bronchopneumonia in children: a comparative randomised study [abstract]. 7th Eur Congr Clin Microbiol Infect Dis 1995: 269
75. Hamill J. Multicentre evalualion of azithromycin and penicillin V in the treatment of acute streplococcal pharyngitis and tonsillitis in children. J Antimicrob Chemother 1993 Jun; 31 Suppl. E: 89-94
76. O'Doherly B, Paediatric Azithromycin Study Group. Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis /tonsillitis. Eur J Clin Microbiol Infect Dis 1996 Sep; 15: 718-24
77. Pacifico L, Scopetti F, Ranucei A, et al. Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. Antimicrob Agents Chemother 1996 Apr; 40: 1005-8
78. Schaad UB, Heynen G. Swiss Tonsillopharyngitis Study Group. Evaluation of the efficacy, safety and toleration of azithromycin vs. penicillin V in the treatment of acute streptococcal pharyngitis in children: results of a multicenter, open comparative study. Pediatr Infect Dis J 1996 Sep; 15: 791-5
79. Still JG. Management of pediatric patients with group A beta-hemolytic Streptococcus pharyngitis: treatment options. Pediatr Infect Dis J 1995 Apr; 14 (4 Suppl.): 57-61
80. Still JG. Azithromycin suspension vs penicillin suspension in treatment of children with streptococcal pharyngitis [abstract]. Clin Pharmacol Ther 1993 Feb; 53: 195
81. Still JG. Treatment of streptococcal pharyngitis in children with five days of azithromycin suspension [abstract]. 34th Interscience Conference of Antimicrobial Agents and Chemotherapy 1994; Orlando, Florida, 246
82. Tregnagh M, Lorenzo H. Streptococcus Pharyngitis Study Group. Azithromycin versus penicillin V in the treatment of pediatric patients with streptocoecal pharyngitis/tonsillitis [abstract]. 4th International Conference tin the Macrolides, Azalides, Streptogramins and Ketolides, 21-23 Jan 1998. Barcelona, Spain
83. De La Lastra R, Azithromycin Streptococcal Pharyngitis Study Group. Efficacy, safety and toleration of azithromycin versus cefaclor for the treatment of acute streptococci pharyngitis in children [abstract]. 4th International Conference on the Macrolides, Azalides, Streptogramins and Ketolides. 21-23 Jan 1998. Barcelona, Spain
84. Treadway G, Azithromycin Pharyngitis Study Group, Comparison of the efficacy, safety and toleration of azithromycin and erythromycin in the treatment of paediatric patients with acute streptococcal pharyngitis [abstract]. 4th International Conference on the Macrolides, Azalides, Streptogramins and Ketolides. 21-23 Jan 1998. Barcelona, Spain
85. Weippl G, Multicentre comparison of azithromycin versus erythromycin in the treatment of paediatric pharyngitis or tonsillitis caused by group A streptococci. J Antimicrob Chemother 1993 Jun; 31 Suppl. E: 95-101
86. Rodriguez AF, Arguedas A, Urruela R, et al. Efficacy and safely of azithromycin (AZI) in the treatment of pediatric patients with acute pharyngitis (AP) due to group A β-hemolytic streptococci (GABHS) [abstract no. P563]. J Clin Microbiol Infect 1997; 3 Suppl. 2: 132-3
87. Pacifico L, Chiesa C. Efficacy of three-day azithromycin vs. ten-day penicillin V in the treatment of Streptococcal pharyngitis [letter]. Pediatr Infect Dis J 1997 May; 16: 542
88. Ficnar B, Huzjak N, Oreskovic K, et al. Azithromycin: 3-day versus 5-day course in the treatment of respiratory tract infections in children. J Chemother 1997 Feb; 9; 38-43
89. Galova K, Sufliarska S, Kukova Z, et al. Multicenter randomized study of two once daily regimens in the initial management of community-acquired respiratory tract infections in 163 children: azithromycin versus ceftibuten. Chemotherapy (Basel) 1996 May-Jun; 42: 231-4
90. Kuková Z, Galová K, Krizan S, et al. A randomised trial comparing two once-daily antimicrobials. ceftibuten (CTI) versus azithromycine (AZI) in therapy of community acquired upper respiratory tract infections (RTI) in children [abstract]. 7th Eur Congr Clin Microbiol Infect Dis 1995: 129
91. Lauvau DVA, Verbist L, Paediatric Azithromycin Study Group. An opcn, multicentre, comparative study of the efficacy and safety of azithromycin and co-amoxiclav in the treatment of upper and lower respiratory tract infections (RT) in children. J Int Med Res 1997; 25: 285-95
92. Manfredi R, Jannuzzi C, Mantero E, et al. Clinical comparative study of azithromycin versus erythromycin in the treatment of acute respiratory tract infections in children. J Chemother 1992 Dec; 4: 364-70
93. Bottaro G, Rotolo N, Bonforte S, et al. Evaluation of the clinical efficacy of azithromycin for acute respiratory infections in children [in Italian]. Clin Ter 1994 Jul; 145: 35-9
94. Gürses N, Kalayci AG, Isek I, et al. Azithromycin in the treatment of acute sinusitis of childhood [abstract]. 7th Eur Congr Clin Microbiol Infect Dis 1995: 269
95. Toscano MA, Marzullo E, Minneci MS, et al. Efficacy and tolerance of azithromycin in respiratory tract infections in children [in Italian]. Minerva Pediatr 1995 Jun; 47: 249-60
96. Ramzan A, Hasnain S, Khan S. An open, noncomparative evaluation of the efficacy, safely and toleration of azithromycin in paediatric infections [abstract], 4th International Conference on the Macrolides, Azalides, Streptogramins and Ketolides; 1998 Jan 21-23; Barcelona, Spain
97. Montero L. A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections. J Antimicrob Chemotehr 1996 Jun; 37 Suppl. C: 125-31
98. Rodriguez-Solares A, Pérez-Gutiérrez F, Prosperi J, et al. A comparative study of the efficacy, safety and tolerance of azithromycin, dicloxacillin and flucloxacillin in the treatment of children with acute skin and skin-structure infections. J Antimicroh Chemother 1993 Jun; 31 Suppl. E: 103-9
99. Tabbara KF, Abu-el-Asrar A, Al-Omar O, et al. Single-dose azithromycin in the treatment of trachoma. A randomized. controlled study. Ophthalmology 1996 May; 103: 842-6
100. Bailey RL, Arullendran P, Whittle HC, et al. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 1993 Aug 21; 342: 453-6
101. Dawson CR, Schachter J, Sallam S, et al. A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clin Infect Dis 1997 Mar; 24: 363-8
102. Meloni G, Meloni T. Azithromycin vs. doxycycline for Mediterranean spotted fever. Pediatr Infect Dis J 1996 Nov; 15: 1042-4
103. Vargas SL, Shenep JL, Flynn PM, et al. Clinical and laboratory observations. Azithromycin for treatment of severe Cryptosporidium diarrhea in two children with cancer. J Pediatr 1993 Jul; 123: 154-0
104. Hicks P, Zwiener RJ, Squires J, et al. Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus. J Pediatr 1996 Aug; 129: 297-300
105. Ramos JT, Saavedra J, Ruiz-Contreras J, et al. Cryptosporidium in patients infected with human immunodeficiency virus: azithromycin revisited [letter]. J Pediatr 1997 Jun; 130: 1009-10
106. Aoyama T, Sunakawa K, Iwata S, et al. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. J Pediatr 1996 Nov; 129: 761-4
107. Ohtsuka Y, Itarada Y, Tsuji Y, et al. Pharmacokinetic and clinical studies on azithromycin in children [in Japanese]. Jpn J Antibiot 1996 Nov; 49: 1039-48
108. Okada T, Machida Y, Fujieda M, et al. Pharmacokinetic and clinical evaluations of azithromycin in the pediatric field [in Japanese]. Jpn J Antibiot 1996 Nov; 49: 1024-9
109. Furukawa S, Okada T. A clinical evaluation of azithromycm in the treatment of pediatric infection [in Japanese]. Jpn J Antibiol 1996 Nov; 49: 1013-23
110. Haruta T, Kohayashi Y. Therapeutic efficacy of azithromycin in pediatrics [in Japanese]. Jpn J Antibiot 1996 Oct; 49: 926-31
111. Ishida Y, Kida K, Matsuda H. Pharmacokinetic and clinical evaluation of azithromycin in pediatric infections [in Japanese]. Jpn J Antibiot 1996 Nov; 49: 1030-308
112. Kobayashi Y, Kino M, Higashino H, et al. Clinical study of a macrolide antibiotic, azithromycin, in pediatric patients [in Japanesel]. Jpn J Antibiot 1996 Nov; 49: 1004-12
113. Kuroda Y, Ito M. Therapy with azithromycin in pediatric infections [in Japanese]. Jpn J Antibiot 1996 Oct; 49: 932-8
114. Nishimura T, Sugita K, Aoki S, et al. Clinical evaluation of azithromycin in pediatric infections [in Japanese]. Jpn J Antibiot 1996 Oct; 49: 917-25
115. Okamoto T, Sekiguchi T. Clinical studies on azithromycin in pediatrics [in Japanese]. Jpn J Antibiot 1996 Oct; 49: 939-46
116. Okumura A, Kuno K. Pharmacokinetic and clinical evaluation of azithromycin in pediatrics [in Japanese]. Jpn J Antibiot 1996 Nov; 49: 994-1003
117. Treadway G, Pontani D. Paediatric safety of azithromycin: worldwide experience. J Antimicrob Chemother 1996 Jun; 37 Suppl. C; 143-9
118. Hopkins SJ, Williams D. Clinical tolerability and safety of azithromycin in children. Pediatr Infect Dis J 1995 Apr; 14 (4) Suppl.: 67-71
119. Treadway G, Pontani D. Comparison of the tolerability of 3-day once-daily azithromycin suspension versus standard treatments for pediatric infectious diseases [abstract no. M288]. Antiinfect Drugs Chemother 1998; 16 Suppl. 1: 47
120. Richborough Pharmaceuticals. ZithromaxTM Capsules, Zithromaz Suspension. Roxborough Pharmaceuticals. A Division of Pfizer Limited, Sandwich, Kent, CT13 9NJ
121. Anonymous. Azithromycin. In: McEvoy GK, editor. AHFS Drug InformationR 97. Bethesda (MD): American Society of Health-System Pharmacists Inc., 1997: 237-9
122. Zimmermann T, Yeates RA, Laufen H, et al. Influence of the antibiotics crythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneimittel Forschung 1996 Feb; 46: 213-7
123. Ripoll L, Reinert P, Pépin L-F, et al. Interaction of macrolides with α-dornase during DNA hydrolysis. J Antimicrob Chemother 1996 May; 37: 987-91
124. Stevens DA. Antifungal interaction in vitro between fluconazole (F), rifabutin (R) and azithromycin (A) [abstract]. Clin Infect Dis 1994 Sep; 19: 578
125. Bartlett JG, Breiman RF, Mandell LA, et al. Guidelines from the Infectious Diseases Society of America. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998; 26: 811-38
126. Anonymous. The choice of antibacterial drugs. Med Lett Drugs Ther 1998 Mar 27; 40 (1023): 33-42
127. Froom J, Culpepper L, Jacobs M, et al. Antimicrobials for acute otitis media? A review from the International Primary Care Network. BMJ 1997; 315: 98-102
128. Pichichero ME, Cohen R. Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. Pediatr Infect Dis J 1997; 16(7): 680-95
129. Kozyrskyj AL, Hildes-Ripstein E, Longstaffe SEA, et al. Treatment of acute otitis media with a shortened course of antibiotics: a meta-analysis. JAMA 1998 Jun 3; 279 (21): 1736-42
130. Seppälä H, Klaukka T, Lehtonen R, et al. Outpatient use of erythromycin: link to increased erythromycin resistance in group A streptococci. Clin Infect Dis 1995; 21: 1378-85
131. Jackson MA, Burry VF, Olson LC, et al. Breakthrough sepsis in macrolide-resistant pneumococcal infection. Pediatr Infect Dis J 1996 Nov; 15: 1049-51
132. Gottlieb T. Drug-resistant Streptococcus pneumoniae: the beginning of the end for many antibiotics? [letter]. Med J Aust 1996 Aug 19; 165: 233-4
133. Sansgiry SS, Sansgiry SS, Cady PS, et al. Cost-effectiveness of azithromycin for the treatment of acute otitis media in a rural population [abstract]. Am J Manage Care 1997 Mar; 3: S53
134. Stewart A, Phillips R. Antibiotic treatment for paediatric streptococcal pharyngitis: estimation of costs in general practice. Br J Med Econ 1994; 7: 123-36
135. Powers JL. Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections. Pediatr Infect Dis J 1996 Sep; 15 Suppl.: 30-7